Please login to the form below

Not currently logged in
Email:
Password:

Roche collaborates with German biotech

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Germany

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Penzberg, Germany. Under the agreement, Kinaxo's phosphoproteomics technology, PhosphoScout, will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement have not been disclosed.

PhosphoScout is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the unbiased analysis of 15,000 phosphorylation sites in a single experiment.

Dr Klaus Godl, Kinaxo's chief scientific officer, commented: "We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs."

Kinaxo also works with Johnson & Johnson, Bayer and Boehringer Ingelheim.

21st October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics